Description

Specifications

• Form: White lyophilized powder
• Standard vial size: 10mg
• Purity: ≥99% (HPLC & Mass Spec verified)
• Sequence: 11-amino-acid peptide derived from the erythropoietin (EPO) helix-B domain
• Storage: Store lyophilized powder at -20°C; refrigerate at 2–8°C once reconstituted

Overview

ARA-290 is a synthetic peptide derived from the helix-B surface region of erythropoietin, engineered to retain EPO’s tissue-protective signaling while eliminating its hematopoietic (red-blood-cell-stimulating) activity.

Mechanism & Research Findings

ARA-290 selectively activates the innate repair receptor (IRR), a heteromeric complex of the EPO receptor and CD131, rather than the classical homodimeric EPO receptor responsible for erythropoiesis. This selectivity allows researchers to study EPO’s cytoprotective and anti-inflammatory signaling — including effects on small-fiber nerve regeneration and neuropathic pain models — entirely independent of confounding changes in red-blood-cell production, making ARA-290 a valuable tool for dissecting EPO’s pleiotropic receptor biology.

Research Applications

• Innate repair receptor (IRR) / CD131 signaling research
• Neuropathic pain and small-fiber nerve regeneration models
• EPO-pathway selectivity research (cytoprotection vs. erythropoiesis)

For laboratory research use only. Not for human consumption, diagnostic, or therapeutic use.